Navigation Links
HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
Date:6/12/2012

CHARLOTTESVILLE, Va., June 12, 2012 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, announced today that they have published a key Review article entitled, Organotypic systems in drug metabolism and toxicity: challenges and opportunities, in Expert Opin. Drug Metab. Toxicol. Authored by Ajit Dash, MD, PhD and HemoShear co-founders Brett R. Blackman, PhD and Brian R. Wamhoff, PhD, this Expert Opinion examines the various approaches to recreating meaningful human biology on the bench and traces the evolution of organotypic systems while discussing intrinsic challenges and opportunities that lie ahead. Furthermore, they cite literature that is the foundation of several biotechnology research companies addressing this issue and discuss major government-funded initiatives to aid the development of these systems.

(Logo:  http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

"High-throughput screening cell-based tools still serve a purpose in compound screening campaigns, but they continue to fail in predicting in vivo response for important and costly pipeline decisions," said Dr. Dash, Director of HemoShear's Liver Surrogate Systems Division. "Further, the limitations of animal models in predicting human safety or drug efficacy continue to negatively impact drug companies' confidence as they make important decisions about whether to enter human clinical trials."

"Our vision as a company is to develop meaningful human-relevant systems so that we can help our biopharmaceutical partners make more meaningful decisions in their pre-clinical pipelines, greatly reducing the risk in their portfolio," said Dr. Wamhoff. "Initial results in our vascular and liver surrogate systems indicate that we can recreate human in vivo biology and response on the bench, which is extremely exciting! Continued development and validation of these systems and disease systems is important to our partners. The science is groundbreaking and the data human-relevant.  We really are thinking about drug discovery from the human perspective."

About HemoShear, LLC
HemoShear LLC is a biotechnology research company that combines its scientific expertise with its proprietary platform technology in research collaborations with pharmaceutical companies to accelerate drug discovery and development. HemoShear has expertise in the areas of human and animal biology, bioinformatics and molecular profiling for target identification and validation, cell-signaling pathway analysis, sophisticated methods to quantify target genes and proteins, assessment of molecular pharmacology, and methods to determine mechanisms of action for drug efficacy and safety.

HemoShear's technology platform can be adapted to replicate the biology of human or animal organ systems in both healthy and disease-prone states by applying physiologically accurate hemodynamic forces to primary cell cultures.  HemoShear is currently collaborating with several large pharmaceutical companies on programs that span the drug discovery and development spectrum.  HemoShear is a privately held company located in Charlottesville, Virginia.  To learn more about HemoShear and our research, please visit our website at www.hemoshear.com.


'/>"/>
SOURCE HemoShear, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
3. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
4. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
5. Delcath Systems, Inc. Secures $20 Million Credit Facility
6. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
7. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
8. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
9. Middle East and Africa Endoscopy Devices Market Outlook to 2017 - Flexible Endoscopes, Rigid Endoscopes, Endoscopy Visualization Systems, Capsule Endoscope Systems and Others
10. New Forecast Shows Patient Monitoring Systems Market to Reach $18.9 billion by 2016
11. Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
(Date:12/6/2016)... Miss. , Dec. 6, 2016 Two ... rescue personnel in a simulated mass casualty event Tuesday ... . The technology debuted before an audience including ... and representatives from Homeland Security, Federal Law Enforcement ... Drone Project, known as HiRO (Health Integrated Rescue Operations), ...
(Date:12/6/2016)...  Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), ... it entered into collaboration with Takeda Pharmaceutical Company ... of NASH and other gastrointestinal (GI) related disorders, ... UNA Oligomer chemistry. The financial terms were not ... and expertise in GI disorders, we are confident ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... ... have until January 15, 2017 to apply for a 2016/2017 California Casualty Thomas ... http://www.calcasathleticsgrant.com . Qualifying schools can receive up to $3,000. , The ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... advisory organization, is proud to announce it has added CXC Solutions (CXC) as ... management solutions. These solutions are tailored to help benefits advisors reduce operating ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... is now offering HIAC particle counting and sizing services for USP 788 and ... instituted the new service as a response to the needs of pharmaceutical and ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for the ... active alerts and even taking an EKG from the watch while sharing these ...
(Date:12/6/2016)... ... December 06, 2016 , ... Keeping Gift Season Safe, In a ... are safe and age-appropriate for their recipients. This is the idea behind Safe Toys ... safety of items that would make good gifts for children. For companies that produce ...
Breaking Medicine News(10 mins):